These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2687812)

  • 21. Assessment of biological responses: what to measure and when.
    Maluish AE; Herberman RB
    Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in the management of biotherapy-related side effects: fatigue.
    Piper BF; Rieger PT; Brophy L; Haeuber D; Hood LE; Lyver A; Sharp E
    Oncol Nurs Forum; 1989; 16(6 Suppl):27-34. PubMed ID: 2480583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
    Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symptom assessment and management of outpatients receiving biotherapy: the application of a symptom report form.
    White CL
    Semin Oncol Nurs; 1992 Nov; 8(4 Suppl 1):23-8. PubMed ID: 1462055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nursing management of patients receiving biological therapy.
    Sandstrom SK
    Semin Oncol Nurs; 1996 May; 12(2):152-62. PubMed ID: 8727802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biotherapy of cancer--III. Proceedings of a symposium; May 19, 1989; San Francisco, California.
    Oncol Nurs Forum; 1989; 16(6 Suppl):3-47. PubMed ID: 2594552
    [No Abstract]   [Full Text] [Related]  

  • 27. Understanding the symptoms of the common cold and influenza.
    Eccles R
    Lancet Infect Dis; 2005 Nov; 5(11):718-25. PubMed ID: 16253889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological response modifiers (BRMs) are often discussed with a narrow focus on the“biological therapies,” ie, the pharmacologically administered form of cytokines, eg, interferon or antagonists of cytokines, eg, tumor necrosis factor blocking agents. Introduction.
    Khardori NM
    Infect Dis Clin North Am; 2011 Dec; 25(4):xiii-xiv. PubMed ID: 22054763
    [No Abstract]   [Full Text] [Related]  

  • 29. Future projections in biotherapy.
    Rieger PT
    Semin Oncol Nurs; 1996 May; 12(2):163-71. PubMed ID: 8727803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptom management for patients receiving biotherapy.
    Rust D; Bell D; Colao D; McMahon S
    Oncol Nurs Forum; 1990; 17(6):964. PubMed ID: 2263527
    [No Abstract]   [Full Text] [Related]  

  • 31. Is fever really a "side-effect" of biological response modifiers?
    Kluger MJ
    Lancet; 1992 Feb; 339(8791):491. PubMed ID: 1346839
    [No Abstract]   [Full Text] [Related]  

  • 32. New directions in combination biotherapy. Proceedings of a symposium. May 19, 1989, San Francisco.
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):1-41. PubMed ID: 2300825
    [No Abstract]   [Full Text] [Related]  

  • 33. BRMs. New drug therapy comes of age.
    Dudjak LA; Fleck AE
    RN; 1991 Oct; 54(10):42-8. PubMed ID: 1925347
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical uses of interferons, interleukins, tumor necrosis factor, monoclonal antibodies, and growth factors in patients with cancer.
    Haynes AL
    J Pediatr Oncol Nurs; 1990 Apr; 7(2):54-5. PubMed ID: 2194505
    [No Abstract]   [Full Text] [Related]  

  • 35. Neurologic toxicity management with BRMs.
    Shelton BN; Sargent CA
    Oncol Nurs Forum; 1990; 17(6):964-5. PubMed ID: 2263528
    [No Abstract]   [Full Text] [Related]  

  • 36. Biological-response modifier--induced emergencies.
    Crum E
    Semin Oncol; 1989 Dec; 16(6):579-87. PubMed ID: 2688117
    [No Abstract]   [Full Text] [Related]  

  • 37. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
    Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
    J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the management of biotherapy-related side effects: flu-like syndrome.
    Haeuber D
    Oncol Nurs Forum; 1989; 16(6 Suppl):35-41. PubMed ID: 2687812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical symptoms of combination biotherapy: a quality-of-life issue.
    Brophy LR; Sharp EJ
    Oncol Nurs Forum; 1991; 18(1 Suppl):25-30. PubMed ID: 1997974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.